Other research analysts have also recently issued reports about the company. Cowen and Company reaffirmed a buy rating on shares of Allergan PLC in a research note on Tuesday, May 24th. Goldman Sachs Group Inc. reaffirmed a buy rating on shares of Allergan PLC in a research note on Wednesday, July 6th. Leerink Swann reaffirmed a buy rating on shares of Allergan PLC in a research note on Thursday, June 30th. Wells Fargo & Co. reaffirmed a buy rating on shares of Allergan PLC in a research note on Friday, June 10th. Finally, Vetr cut Allergan PLC from a strong-buy rating to a buy rating and set a $275.94 price objective on the stock. in a research note on Thursday, June 2nd. Seven analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of Buy and a consensus target price of $308.54.
Allergan PLC (NYSE:AGN) opened at 243.94 on Tuesday. The firm has a market capitalization of $96.59 billion, a P/E ratio of 23.23 and a beta of 0.73. Allergan PLC has a 1-year low of $195.50 and a 1-year high of $322.68. The company’s 50-day moving average price is $244.66 and its 200-day moving average price is $242.69.
Allergan PLC (NYSE:AGN) last released its quarterly earnings results on Monday, August 8th. The company reported $3.35 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.34 by $0.01. Allergan PLC had a return on equity of 7.67% and a net margin of 28.06%. The business had revenue of $3.68 billion for the quarter, compared to the consensus estimate of $4.10 billion. During the same quarter last year, the business posted $4.41 earnings per share. The company’s revenue for the quarter was up 1.0% on a year-over-year basis. Equities research analysts expect that Allergan PLC will post $14.01 earnings per share for the current fiscal year.
A number of large investors have recently bought and sold shares of AGN. Barnett & Company Inc. bought a new stake in Allergan PLC during the first quarter worth approximately $111,000. Ropes Wealth Advisors LLC increased its stake in Allergan PLC by 13.2% in the first quarter. Ropes Wealth Advisors LLC now owns 497 shares of the company’s stock worth $133,000 after buying an additional 58 shares during the period. Livingston Group Asset Management CO operating as Southport Capital Management bought a new stake in Allergan PLC during the second quarter worth approximately $125,000. Trust Co. of Vermont increased its stake in Allergan PLC by 19.5% in the second quarter. Trust Co. of Vermont now owns 545 shares of the company’s stock worth $126,000 after buying an additional 89 shares during the period. Finally, Integrated Investment Consultants LLC increased its stake in Allergan PLC by 35.2% in the second quarter. Integrated Investment Consultants LLC now owns 592 shares of the company’s stock worth $137,000 after buying an additional 154 shares during the period. 85.19% of the stock is owned by institutional investors and hedge funds.
Allergan PLC Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC and related companies with MarketBeat.com's FREE daily email newsletter.